<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01094834</url>
  </required_header>
  <id_info>
    <org_study_id>DWP05195-P002</org_study_id>
    <nct_id>NCT01094834</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Study of DWP05195 in Healthy Adult Subjects</brief_title>
  <official_title>A Multiple Dose Study To Determine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP05195 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and&#xD;
      pharmacodynamics of multiple administered DWP05195 in healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of safety &amp; tolerability: adverse events, vital signs, 12-Lead ECG, laboratory safety variables and physical examination</measure>
    <time_frame>17 days after drug administration</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy Adult Volunteers</condition>
  <arm_group>
    <arm_group_label>DWP05195</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP05195</intervention_name>
    <description>tablets, oral administration, multiple administration</description>
    <arm_group_label>DWP05195</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult male subjects aged 20 to 45 years&#xD;
&#xD;
          2. The subject has a Body weight ≥50 kg and &lt;90 kg and Body Mass Index(BMI) ≥19.0 kg/m2&#xD;
             and &lt; 27.0 kg/m2.&#xD;
&#xD;
          3. A subject who provided written informed consent to participate in this study and&#xD;
             cooperative with regard to compliance with study related constraints&#xD;
&#xD;
          4. A Subject who was judged to be healthy by the investigator to participate in this&#xD;
             study based on screening results (according to standard reference index updated&#xD;
             recently)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. A subject with sign or symptoms or previously diagnosed disease of respiratory,&#xD;
        cardiovascular, endocrinology, liver, kidney, gastrointestinal, hematology, neurology and&#xD;
        psychology function or other significant diseases and history or suspicion of current drug&#xD;
        abuse and alcohol abuse 2. A subject who had any allergic history to any drug (prescription&#xD;
        drug or OTC medication etc.) 3. A subject who had received treatment with below listed drug&#xD;
        within specified period prior to the first dose of study medication&#xD;
&#xD;
          -  Within last 1 month : drug or food known CYP1A2 inducer or inhibitor&#xD;
&#xD;
          -  Within 2 weeks : Prescribed or herbal or Non-prescribed medicine&#xD;
&#xD;
          -  Within 3 days : Consumption of grapefruit juice/grapefruit containing products or&#xD;
             orange juice/orange containing products, garlic extracted functional foods&#xD;
&#xD;
          -  Within 3 days : Consumption of alcohol or caffeine 4. A subject who had participated&#xD;
             in any other clinical study within the last 12 weeks 5. A subject from whom over 400mL&#xD;
             of blood was sampled(whole blood or plasma donation, etc.) within last 12 weeks 6. A&#xD;
             Subject with the known evidence of the following infections or drug abuse&#xD;
&#xD;
          -  HIV, HBs, HCV&#xD;
&#xD;
          -  cannabinoid, opioid, amphetamine, cocaine, barbiturate, benzodiazepine 7. Smoker or&#xD;
             smoking cessation within 1 month or ex-smoker with positive results by cotinine test&#xD;
             8. AST or ALT greater than 1.5 times the upper limit of reference range or QTc &gt; 430&#xD;
             msec base on screening results 9. Blood pressure : SBP≥140mmHg, DBP≤85mmHg 10. A&#xD;
             subject judged ineligible by the investigator to participate in this study for other&#xD;
             reason containing clinical laboratory tests&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>March 26, 2010</study_first_submitted>
  <study_first_submitted_qc>March 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2010</study_first_posted>
  <last_update_submitted>February 8, 2011</last_update_submitted>
  <last_update_submitted_qc>February 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Daewoong Pharmaceutical Co.LTD.</name_title>
    <organization>Daewoong Pharmaceutical Co.LTD.</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

